Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

adc therapeutics antibody drug conjugates

News and Trends 9 Jul 2019

Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy

Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M) Series E round to finance the development of a phase II antibody-drug conjugate treatment for blood cancer. With its big Series E complete, the company is in a good financial position to prepare for the commercialization of its lead candidate […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

biontech cancer vaccine mrna immunotherapy

News and Trends 9 Jul 2019

BioNTech Raises Whopping €290M to Fund Personalized mRNA Vaccines for Cancer

In one of the biggest ever funding rounds in European biotech, the German company BioNTech has raised a Series B of €289.5M ($325M) to develop individualized cancer vaccines. BioNTech will use the money to fuel the clinical development of the company’s lead program — an individualized mRNA-based immunotherapy for treating melanoma, which completed a phase […]

July 9, 2019 - 3 minutesmins - By Jonathan Smith

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Jul 2019

European Biotech: The Insider View

How has CRISPR changed drug development? How do you negotiate a good partnership? What are some of the hard decisions to make in founding a biotech? These are some of the questions that industry experts answered at Labiotech’s first Insider Day. Held exclusively for members, Labiotech’s first Insider Day aimed to explore the different aspects […]

July 7, 2019 - 10 minutesmins - By Jonathan Smith

valbiotis food supplement prediabetes

News and Trends 5 Jul 2019

French Biotech’s Plant Extract Cuts Blood Glucose in Prediabetic People

A plant extract developed by the French biotech Valbiotis is the first food supplement to reduce blood glucose levels in people at high risk of developing type 2 diabetes. In a phase IIa trial, Valbiotis compared its food supplement with a placebo in 51 people with prediabetes. After six months, the supplement had reduced blood […]

July 5, 2019 - 2 minutesmins - By Jonathan Smith

melanoma yukin therapeutics antibody cancer nice

Startup Scout 5 Jul 2019

This Biotech Helps the Immune System to Infiltrate and Destroy Tumors

The Nice-based biotech company Yukin Therapeutics is developing drugs that can work together with checkpoint inhibitors to help the immune system smash tumors such as melanoma. Mission: To develop a drug that can change the tumor microenvironment to allow the immune system to infiltrate and destroy the tumor more effectively. This could give a big […]

July 5, 2019 - 3 minutesmins - By Jonathan Smith

ADVERTISEMENT

lupus autoimmune disease neutrophil citryll

News and Trends 4 Jul 2019

Dutch Antibodies for Autoimmune Diseases Boosted by €15M Series A

The Dutch biotech Citryll has raised €15M to develop antibodies that could fight autoimmune and inflammatory diseases more effectively than current treatments by inhibiting the innate immune system. The Series A funds will be used to launch the clinical development of Citryll’s lead antibody, which is designed to treat the autoimmune condition lupus. The money […]

July 4, 2019 - 2 minutesmins - By Jonathan Smith

amoeba biocontol rust disease agriculture

More News! 4 Jul 2019

First Eco-Friendly Treatment Stops Fungal Crop Disease

An eco-friendly antifungal treatment developed by the French biotech Amoéba has reduced rust infections in legumes by 85% in a recent field trial. Rust is a plant disease caused by fungi that is very hard to treat. Although chemical fungicides can be used against it, these are often expensive and harmful to other organisms, including […]

July 4, 2019 - 3 minutesmins - By Jonathan Smith

viiv healthcare hiv treatment

News and Trends 3 Jul 2019

EU Approves Two-Drug Pill as First-Line Treatment for HIV

The two-drug pill Dovato, developed by the UK company ViiV Healthcare, has been approved as a first-line treatment for HIV, potentially causing fewer long-term side effects than current three-drug antiretroviral regimens. HIV patients currently need to take three or more antiretroviral drugs per day to keep the infection at bay. As they get older, these […]

July 3, 2019 - 2 minutesmins - By Jonathan Smith

Storm Therapeutics Keith Blundy

Interview 3 Jul 2019

Meet the First Company in the Brand New Field of Epitranscriptomics

A whole new therapeutic area is taking medical research by storm. In Cambridge, UK, the company Storm Therapeutics is leading the development of the first treatments to target a new layer of genetic information encoded in the RNA. The term ‘epitranscriptomics’ did not exist a decade ago. It was coined in 2012, when scientists started […]

July 3, 2019 - 5 minutesmins - By Clara Rodríguez Fernández

acne s biomedic skinbiotherapeutics skin microbiome

News and Trends 2 Jul 2019

Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People

A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […]

July 2, 2019 - 3 minutesmins - By Jonathan Smith

MolMed Zalmoxis cell therapy

News and Trends 1 Jul 2019

Approval Status of Cancer Cell Therapy at Risk After Halting Phase III Trial

Following an unfavorable interim analysis, Milan-based MolMed has suspended a phase III trial of its cell therapy Zalmoxis that could threaten the conditional marketing authorization the treatment received in 2016. The halted clinical trial was evaluating the effects of Zalmoxis on patients with high-risk leukemia that have received a bone marrow transplant. The cell therapy […]

July 1, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT